Publication
Membranoproliferative glomerulonephritis associated with type II cryoglobulinaemia in a renal transplant patient with hepatitis C
| dc.contributor.author | Bento, C. | |
| dc.contributor.author | Malheiro, J. | |
| dc.contributor.author | Almeida, M. | |
| dc.contributor.author | Martins, L. | |
| dc.contributor.author | Dias, L. | |
| dc.contributor.author | Vizcaíno, J. | |
| dc.contributor.author | Castro-Henriques, A. | |
| dc.date.accessioned | 2015-02-02T13:38:25Z | |
| dc.date.available | 2015-02-02T13:38:25Z | |
| dc.date.issued | 2014 | |
| dc.description.abstract | The most common HCV-related nephropathy is membranoproliferative glomerulonephritis (MPGN), usually in the context of cryoglobulinaemia. The treatment of this entity is not consensual and represents a challenge to clinicians. We report a case of membranoproliferative glomerulonephritis associated with cryoglobulinaemia type II in a 46-year-old Caucasian male recipient of a deceased kidney transplant in 2010. His baseline serum creatinine (SCr) was 1.1 mg/dl. After three years post-transplantation, he presented with nephritic syndrome in association with renal function impairment (SCr – 2.1 mg/dl). The laboratory tests revealed positive rheumatoid factor, hypocomplementaemia and a positive cryocrit with type II cryoglobulinaemia. Antinuclear autoantibodies and anti-double stranded DNA antibodies were negative. Despite the presence of anti-HCV antibodies, the viral load remained undetectable. The allograft biopsy showed lesions compatible with membranoproliferative glomerulonephritis, with staining in the immunofluorescence for granular IgM and C3 and no C4d. He was treated with methylprednisolone pulses followed by oral prednisolone in association with rituximab. Two months after the last dose of rituximab, the SCr improved to 1.27 mg/dl, the proteinuria decreased and serum C3 levels normalized. Cryogloglobulins and rheumatoid factor became negative and HCV RNA remained undetectable. The patient was lost for follow-up. In our case, the treatment with rituximab resulted in a favourable outcome, although a longer follow-up period may be needed to evaluate the clinical response, since other studies reported high relapse rates. | por |
| dc.identifier.citation | Port J Nephrol Hypert 2014; 28(2): 164-167 | por |
| dc.identifier.uri | http://hdl.handle.net/10400.16/1743 | |
| dc.language.iso | eng | por |
| dc.peerreviewed | yes | por |
| dc.publisher | Sociedade Portuguesa de Nefrologia | por |
| dc.relation.publisherversion | http://www.spnefro.pt/RPNH/PDFs/n2_2014/artigo_11.pdf | por |
| dc.subject | Cryoglobulinaemia | por |
| dc.subject | hepatitis C | por |
| dc.subject | kidney transplant | por |
| dc.subject | membranoproliferative glomerulonephritis | por |
| dc.subject | rituximab | por |
| dc.title | Membranoproliferative glomerulonephritis associated with type II cryoglobulinaemia in a renal transplant patient with hepatitis C | por |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.citation.conferencePlace | Portugal | por |
| oaire.citation.endPage | 167 | por |
| oaire.citation.startPage | 164 | por |
| oaire.citation.title | Portuguese Journal of Nephrology & Hypertension | por |
| oaire.citation.volume | 28(2) | por |
| rcaap.rights | openAccess | por |
| rcaap.type | article | por |